Prognosis in HIV-infected patients with non-small cell lung cancer

K. Sigel*, K. Crothers, R. Dubrow, K. Krauskopf, J. Jao, C. Sigel, A. Moskowitz, J. Wisnivesky

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

46 Scopus citations


Background:We conducted a population-based study to evaluate whether non-small cell lung cancer (NSCLC) prognosis was worse in HIV-infected compared with HIV-uninfected patients.Methods:Using the Surveillance, Epidemiology and End Results (SEER) registry linked to Medicare claims, we identified 267 HIV-infected patients and 1428 similar controls with no evidence of HIV diagnosed with NSCLC between 1996 and 2007. We used conditional probability function (CPF) analyses to compare survival by HIV status accounting for an increased risk of non-lung cancer death (competing risks) in HIV-infected patients. We used multivariable CPF regression to evaluate lung cancer prognosis by HIV status adjusted for confounders.Results:Stage at presentation and use of stage-appropriate lung cancer treatment did not differ by HIV status. Median survival was 6 months (95% confidence interval (CI): 5-8 months) among HIV-infected NSCLC patients compared with 20 months (95% CI: 17-23 months) in patients without evidence of HIV. Multivariable CPF regression showed that HIV was associated with a greater risk of lung cancer-specific death after controlling for confounders and competing risks.Conclusion:NSCLC patients with HIV have a poorer prognosis than patients without evidence of HIV. NSCLC may exhibit more aggressive behaviour in the setting of HIV.

Original languageEnglish (US)
Pages (from-to)1974-1980
Number of pages7
JournalBritish Journal of Cancer
Issue number7
StatePublished - Oct 1 2013


  • HIV
  • competing risks
  • immunosuppression
  • lung cancer epidemiology
  • lung cancer prognosis
  • non-small cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Prognosis in HIV-infected patients with non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this